Leukemia, Myelomonocytic, Chronic × 90 days × Clear all
NCT00544115 2026-06-02

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT06904066 2026-06-02

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
NCT04195633 2026-05-29

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled
NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
NCT03326921 2026-05-18

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1 Recruiting
24 enrolled
NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
NCT04996875 2026-05-05

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT03670966 2026-05-04

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT03289910 2026-04-13

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
25 enrolled 15 charts
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled